European Archives - Page 805 of 1216 - European Medical Journal

EMJ Cardiology 7.1 2019

In this edition of EMJ Cardiology, we present an in-depth review of the European Society of Cardiology (ESC) Congress 2019, including expert sessions…

Th17 Signature, Autoimmunity, and Differentially Expressed Genes in Cardiomyopathy and Heart Failure

Myocarditis is a common precursor to dilated cardiomyopathy (DCM) and together they are the cause of approximately half of all heart transplants…

Digital Ripples in the Cardiovascular Pond

An acceptance has slowly emerged within the healthcare community that limitations exist in its ability to efficiently, and most importantly sustainably…

European Society of Cardiology Chronic Coronary Syndromes Guidelines Review

New guidelines for the diagnosis and management of chronic coronary syndromes (CCS)1 were released during the 2019 European Society of Cardiology (ESC) Congress.

Summary of Artificial Intelligence in Echocardiography for Standard Clinical Metrics

This study sought to validate the use of artificial intelligence (AI) for analysis of an echocardiogram, in a clinical scenario.

ESC 2019 Interview: Prof Thomas F. Lüscher

Prof Thomas F. Lüscher, MD, FRCP, FESC | Professor of Cardiology, Imperial College London, National Heart and Lung Institute, London, UK

Generating Proliferative Induced Cardiomyocyte Precursor Cells

Ischaemic injury of the adult human heart results in irreversible loss of cardiomyocytes (CM), leading to fibrosis, and eventually heart failure.

Out-of-Hospital Cardiac Arrest - Incidence of Coronary Artery Disease, Comorbidity, and Survival

Data from the 2012 European Cardiovascular Disease Statistics show that 20% of all deaths are caused by coronary artery disease (CAD), with cardiac arrest..

Single-Centre Experience with Different Regimes of Antiplatelet Therapy and Oral Anticoagulation in Transcatheter Aortic Valve Replacement

Antithrombotic therapy in transcatheter aortic valve replacement (TAVR) is highly controversial. Dual antiplatelet therapy (DAPT) for 3–6 months…

Icosapent Ethyl for the Prevention of Cardiovascular Events

Based on genetic evidence, it is now known that triglyceride-rich lipoproteins lead to atherosclerosis and local inflammation, which can result in…